TIGO
17.11.2021 23:02:08 CET | Business Wire | Press release
Tigo Energy Inc. , the solar industry’s worldwide leader in Flex MLPE (Module Level Power Electronics), announced today that Australia’s SCE Energy Solutions has deployed more than 7MW of monitored solar energy across 800 commercial, residential, and rural solar installations. SCE has leveraged the Tigo Energy Intelligence (EI) software platform to expand its service-oriented approach to maximize the benefits of the Tigo platform for its clients across Australia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211117006255/en/
SCE Energy Solutions uses the advanced chart pages for fleet management and kiosk view from Tigo Energy to enable two unique services for clients. Using the data provided by the EI software platform, SCE conducts weekly maintenance checks for system owners to ensure their systems are operating at peak performance. The kiosk view of the EI platform enables SCE to set up a screen for residential and commercial system owners through which they can showcase energy production and their commitment to renewable energy customers, colleagues, and friends.
“In the Tigo monitoring system we have the best available technology to improve the ROI for our customers, and it has a tremendously positive impact for the many businesses that previously wastes up to 50 percent of the energy they pay for,” said Jon De Martin, CEO and managing director at SCE Energy Solutions. “The kiosk feature of the Tigo Energy Intelligence system provides a powerful way for us to make solar visible, displaying the live energy statistics of our customers’ systems, which they can proudly showcase in public spaces at their business locations.”
SCE Energy Solutions has used Tigo TS4 Flex MLPE optimizers with remote module level monitoring since 2012. Since that time, SCE has implemented Tigo’s technology to service system owners throughout the Commonwealth of Australia, monitor their fleet remotely, and help customers highlight their investments in solar energy. Additionally, SCE provides critical feedback to Tigo for continuous improvement to the platform.
“We support installers’ revenue and strategic goals through a holistic approach to energy management, and SCE Energy Solutions is the ideal Tigo customer because they push the technological envelope and embrace innovation,” says Archie Roboostoff, software vice-president at Tigo Energy. “The SCE team exercises every aspect of our EI software solution to service their customers, reduce truck rolls, optimize energy generation, and maximize solar ROI for customers across Australia. We greatly appreciate the dedication SCE brings to their system owners.”
With more than 40,000 sites monitored worldwide, Tigo Energy processes 47,000 data points per second, resulting in almost a petabyte of monitoring and efficiency data. The platform is available on the internet and as a mobile application named Tigo EI on the Apple App Store and Google Play . To see the EI in action for SCE Energy Solutions, please see the unique insights SCE offers into a live solar site in Australia, here: https://ei.tigoenergy.com/p/C-O7B12J5FVS .
To learn more about Tigo Energy, visit www.tigoenergy.com .
About Tigo Energy
Tigo Energy is the worldwide leader in Flex MLPE (Module Level Power Electronics) with innovative solutions that increase solar energy production, decrease operating costs, and significantly enhance safety of solar energy systems. The Tigo TS4 platform maximizes the benefit of solar and provides customers with the most scalable, versatile, and reliable MLPE solution available. Tigo was founded in Silicon Valley in 2007 to accelerate the adoption of solar energy worldwide. Tigo systems operate on seven continents and produce gigawatt hours of reliable, clean, affordable, and safe solar energy daily. With a global team, Tigo Energy is dedicated to making the best MLPE on earth so more people can enjoy the benefits of solar. Find us online at www.tigoenergy.com .
About SCE Energy Solutions
SCE Energy Solutions is an award-winning sustainability business that prides itself on providing only the highest quality product and latest technologies available for their commercial, rural and residential customers. They have made it their mission to find technologies where clients can gain control of energy costs. This means developing a renewable energy system that is simple & easy to use with predictable payments and a 25-year warranty. We employ a unique five-step-plan: schedule a call, design the best possible system, install that system, get environmentally certified, and then SCE conducts weekly performance checks. They service all areas of Australia and are located in Concord NSW, Australia. For more information, go to www.sce-energysolutions.com.au .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211117006255/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom